Defendant
1 case as defendant.
Company overview. Wockhardt Ltd. (NSE: WOCKPHARMA; BSE: 532300) is an Indian pharmaceutical and biotechnology company founded in 1967 by Dr. Habil Khorakiwala and headquartered in Mumbai. It is a publicly listed, independent company — not a subsidiary — with a global affiliate structure that includes Wockhardt Bio AG (Switzerland) and Wockhardt USA LLC (Parsippany, New Jersey). Reported headcount varies by source and year, generally in the roughly 2,500–4,100 range, and FY26 revenue was about ₹3,373 crore (~$375–400M). Figures should be treated as approximate given source variance.
Products / services / operations. Wockhardt manufactures and markets pharmaceutical formulations and branded generics, biopharmaceuticals/biosimilars (notably anti-diabetic), nutrition products, vaccines, and active pharmaceutical ingredients, with manufacturing in India, the UK, Ireland, France, and the US. It is known for sterile injectables and complex generics, and has invested heavily in novel antibiotic discovery for antimicrobial resistance, with NCEs launched in India (Emrok/Emrok O) and a late-stage pipeline candidate (zidebactam/cefepime). The company reports roughly 3,290 cumulative patent filings and 859 grants.
Patent-litigation posture. Wockhardt is an operating company and, in the tracked data, appears solely as a defendant (0 plaintiff cases, 1 defendant case). The single tracked suit is a Hatch-Waxman/ANDA dispute: Jazz Pharmaceuticals v. Wockhardt Bio AG et al., filed July 16, 2015 in the U.S. District Court for the District of New Jersey. That venue is consistent with Wockhardt USA's New Jersey principal place of business; the cases do not cluster in plaintiff-friendly venues such as the Eastern District of Texas.
Notable cases / context. In the Jazz matter, Wockhardt sought approval of a generic 500 mg/mL sodium oxybate oral solution (reference drug Xyrem) via ANDA No. 207526 and filed Paragraph IV certifications; Jazz sued on multiple Orange Book-listed patents. Wockhardt also filed inter partes review petitions against Jazz patents at the PTAB (e.g., IPR2015-01815, IPR2015-01820, IPR2016-00370). The parties settled in 2016, and a consent judgment followed in 2018. This is routine generic-entry litigation rather than patent-assertion activity.
Jazz sued Wockhardt entities in D.N.J. involving the '106 patent. The case was closed, settled, and Wockhardt was later terminated from the related IPR.